The MnemOS Clarity is LAZARUS PHARMACEUTICALS' flagship elderly cognitive support BCI, engineered specifically for patients presenting with mild-to-moderate neurodegenerative conditions including Alzheimer's-spectrum dementia, vascular cognitive impairment, and age-associated memory consolidation failure. The device deploys a 512-electrode high-resolution hippocampal interface combined with a prefrontal scaffold array, working in concert to provide real-time memory encoding assistance — intercepting failing consolidation events and routing them through an onboard neuromorphic co-processor that reconstructs and re-presents memory traces during retrieval attempts. The system does not store raw memory data on-device; instead, it maintains a dynamic pattern-completion model trained on the individual patient's neural signature over a 30-day calibration period. Integrated pharmaceutical microdosing ports allow the device to interface with LAZARUS's NeuroChem drip series, delivering targeted acetylcholine precursors and BDNF analogues at the site of hippocampal interface contact, significantly outperforming systemic pharmaceutical approaches in clinical trials.

In GLMZ, where the population skews heavily toward augmentation-extended lifespans creating an unprecedented cohort of individuals living into their 120s and 130s, dementia has become a quiet epidemic that the city's gleaming transhumanist aesthetic struggles to accommodate. The MnemOS Clarity is both a medical triumph and a cultural flashpoint — families speak of loved ones 'coming back' after installation, of grandparents who had lost decades of identity suddenly able to recognize grandchildren again. But the device also raises uncomfortable questions about authenticity and continuity of self: when a patient's memories are being pattern-completed by a neuromorphic chip, are they remembering, or being told a story the machine believes they should remember? LAZARUS's own ethics board has published three conflicting position papers on the question, none conclusive.